Inpatient Management of HS: A Single-Center Retrospective Study

Inpatient Management of HS: A Single-Center Retrospective Study

Summary Verified By: Narges Bermudez, M.D. | University of Miami/Jackson Memorial Hospital

January 1, 2026

This plain-language research summary was generated by AI, courtesy of HS Simplified.

Inpatient Management of HS: A Single-Center Retrospective Study

Hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps, significantly impacts patient quality of life, necessitating frequent hospital visits for severe flare-ups. This study from the University of Miami highlights the need for specialized dermatology care in managing HS flares in the inpatient setting, revealing that dermatologist-led interventions can shorten hospital stays and speed up biologic therapy—advanced treatments targeting specific immune responses.

How Hospitals Treat Hidradenitis Suppurativa (HS) Flares

Hidradenitis suppurativa (HS) is a long-lasting skin disease that causes painful bumps, swelling, and pus-filled lumps under the skin, often in areas like the armpits and groin. These bumps can break open and leak fluid, making people feel very uncomfortable and affecting their daily lives. When the pain and drainage get really bad, some people with HS have to go to the hospital for help.

Who Is Affected?

In this study, Dr. Lev-Tov and colleagues looked at adults with HS who were admitted to the University of Miami Hospital between 2017 and 2023. Nearly half of the 44 patients were Black, about half were women, and the average age was 38. Many patients had other health problems like obesity (41%), type 2 diabetes (25%), and high blood pressure (18%).

Symptoms and Why People Go to the Hospital

The main reasons patients went to the hospital were pain (100%) and drainage from their skin (68%). Most people had severe HS, called Hurley stage III, which means the disease had spread and caused tunnels under the skin. Many had bumps in more than one body area.

How Were Patients Treated in the Hospital?

Patients were cared for either by the dermatology team (skin doctors) or the internal medicine team (doctors who treat many types of diseases). Most patients got intravenous (IV) steroids—medicines that help reduce swelling—and antibiotics to fight infection. The most common antibiotics were ertapenem and vancomycin. Some also got pain medicine to help them feel better.

Results: Did Hospital Care Help?

Most patients stayed in the hospital for about 6 to 7 days. After treatment, about 82% said their pain was better, and 30% had less drainage. Most patients were given medicines to take at home and told to see a dermatologist (skin doctor) soon after leaving the hospital.

Who Takes Care of HS Patients Best?

Patients who were treated by the dermatology team stayed in the hospital for a shorter time (about 5 days) compared to those cared for by the internal medicine team (about 9 days). They also started special medicines called biologics—which can control HS—faster after leaving the hospital. Biologics are advanced medicines made from living things and are used to help the immune system work better.

Limitations of the Study

This study was only done at one hospital and included a small number of patients, so the results might not apply to everyone with HS. Also, the study looked back at medical records, which means some details could have been missed. Some patients had to come back to the hospital for another flare, showing that treating HS can be very hard and people may need more help even after leaving the hospital.

Why Is This Important?

This study shows that specialized skin doctors (dermatologists) may help people with HS get better faster and start important treatments sooner. It also tells us that HS is a tough disease that affects mostly young adults and can be very painful. The results suggest that hospitals should have plans or special teams to care for people with HS during severe flares to help them recover as quickly as possible.

Read the original paper

Author(s)

Narges Maskan Bermudez, Marita Yaghi, Scott A Elman, Robert S Kirsner, Hadar Lev-Tov

Stay connected with the latest news, research updates, and community stories from the HS Foundation.

Sign up for our email newsletter